NO325181B1 - Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor - Google Patents
Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor Download PDFInfo
- Publication number
- NO325181B1 NO325181B1 NO20032252A NO20032252A NO325181B1 NO 325181 B1 NO325181 B1 NO 325181B1 NO 20032252 A NO20032252 A NO 20032252A NO 20032252 A NO20032252 A NO 20032252A NO 325181 B1 NO325181 B1 NO 325181B1
- Authority
- NO
- Norway
- Prior art keywords
- pyrazine
- piperazinyl
- mmol
- title compound
- oxy
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims description 28
- 229940076279 serotonin Drugs 0.000 title claims description 10
- 239000000556 agonist Substances 0.000 title description 6
- HCGFLVDMFDHYJD-UHFFFAOYSA-N 2-piperazin-1-ylpyrazine Chemical class C1CNCCN1C1=CN=CC=N1 HCGFLVDMFDHYJD-UHFFFAOYSA-N 0.000 title description 3
- 239000005557 antagonist Substances 0.000 title description 3
- 108091005479 5-HT2 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 317
- 229910052757 nitrogen Inorganic materials 0.000 claims description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims description 89
- -1 1 -indanyloxy, 2-indanyloxy Chemical group 0.000 claims description 74
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 71
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 36
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims description 29
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000003216 pyrazines Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 11
- 150000003230 pyrimidines Chemical class 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 208000030814 Eating disease Diseases 0.000 claims description 8
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 8
- 235000014632 disordered eating Nutrition 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 150000003222 pyridines Chemical class 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- IIYVNMXPYWIJBL-UHFFFAOYSA-N 4-(trifluoromethyl)pyridine Chemical class FC(F)(F)C1=CC=NC=C1 IIYVNMXPYWIJBL-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 201000009032 substance abuse Diseases 0.000 claims description 5
- 231100000736 substance abuse Toxicity 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- WLYGONWLTCNUAJ-UHFFFAOYSA-N 1-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethyl]indole Chemical compound C1=CC2=CC=CC=C2N1CCOC(N=1)=CN=CC=1N1CCNCC1 WLYGONWLTCNUAJ-UHFFFAOYSA-N 0.000 claims description 4
- ONEWTSTYTVDELU-UHFFFAOYSA-N 2-(2-phenylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCC1=CC=CC=C1 ONEWTSTYTVDELU-UHFFFAOYSA-N 0.000 claims description 4
- HZNHDQJKDHRQNV-UHFFFAOYSA-N 2-(naphthalen-1-ylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC2=CC=CC=C2C=1COC(N=1)=CN=CC=1N1CCNCC1 HZNHDQJKDHRQNV-UHFFFAOYSA-N 0.000 claims description 4
- CELNOZABGKVYCG-UHFFFAOYSA-N 2-[(2-chlorophenyl)methylsulfanyl]-6-piperazin-1-ylpyrazine Chemical compound ClC1=CC=CC=C1CSC1=CN=CC(N2CCNCC2)=N1 CELNOZABGKVYCG-UHFFFAOYSA-N 0.000 claims description 4
- VKOLTRJZQDPECX-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 VKOLTRJZQDPECX-UHFFFAOYSA-N 0.000 claims description 4
- VOWRKUOBQLCBJI-UHFFFAOYSA-N 2-[(2-phenoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=C(OC=2C=CC=CC=2)C=1COC(N=1)=CN=CC=1N1CCNCC1 VOWRKUOBQLCBJI-UHFFFAOYSA-N 0.000 claims description 4
- FPPQVDJKEFJQSA-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound FC1=CC(F)=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 FPPQVDJKEFJQSA-UHFFFAOYSA-N 0.000 claims description 4
- IBYJQSYRBUBZJX-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 IBYJQSYRBUBZJX-UHFFFAOYSA-N 0.000 claims description 4
- XDOYAEMEIBUWNM-UHFFFAOYSA-N 2-[(3-phenylmethoxyphenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1COC(N=1)=NC=CC=1N1CCNCC1 XDOYAEMEIBUWNM-UHFFFAOYSA-N 0.000 claims description 4
- VIVXNAQRWKTJPF-UHFFFAOYSA-N 2-[1-(3-fluorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC(F)=CC=1C(C)OC(N=1)=CN=CC=1N1CCNCC1 VIVXNAQRWKTJPF-UHFFFAOYSA-N 0.000 claims description 4
- MYBKNHDSVNZGDM-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1 MYBKNHDSVNZGDM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- UXJDGSAVALXBTN-UHFFFAOYSA-N 3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]benzonitrile Chemical compound N#CC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 UXJDGSAVALXBTN-UHFFFAOYSA-N 0.000 claims description 4
- CPVBWHBWLRSCHV-UHFFFAOYSA-N 4-[(2-methoxyphenyl)methoxy]-2-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC=C1COC1=CC=NC(N2CCNCC2)=N1 CPVBWHBWLRSCHV-UHFFFAOYSA-N 0.000 claims description 4
- ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 4-phenylmethoxy-2-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=1)=CC=NC=1N1CCNCC1 ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- CUVLQUXETABQKG-UHFFFAOYSA-N 2-(1-phenylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1C(C)OC(N=1)=CN=CC=1N1CCNCC1 CUVLQUXETABQKG-UHFFFAOYSA-N 0.000 claims description 3
- ZJRXYNVDTHFHHD-UHFFFAOYSA-N 2-(2-naphthalen-2-ylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=C2C=CC=CC2=CC=1CCOC(N=1)=CN=CC=1N1CCNCC1 ZJRXYNVDTHFHHD-UHFFFAOYSA-N 0.000 claims description 3
- LGQFYTYRWGWUEY-UHFFFAOYSA-N 2-(2-phenylethylsulfanyl)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1SCCC1=CC=CC=C1 LGQFYTYRWGWUEY-UHFFFAOYSA-N 0.000 claims description 3
- MCEYUYLACAMCON-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-yloxy)-6-piperazin-1-ylpyrazine Chemical compound C1CNCCN1C1=CN=CC(OC2C3=CC=CC=C3OCC2)=N1 MCEYUYLACAMCON-UHFFFAOYSA-N 0.000 claims description 3
- HHNFHINMJNAQNA-UHFFFAOYSA-N 2-(4-phenoxybutoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1OCCCCOC(N=1)=CN=CC=1N1CCNCC1 HHNFHINMJNAQNA-UHFFFAOYSA-N 0.000 claims description 3
- CMKZSOBBCDDCME-UHFFFAOYSA-N 2-(5-phenoxypentoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCCCCOC1=CC=CC=C1 CMKZSOBBCDDCME-UHFFFAOYSA-N 0.000 claims description 3
- ZQVATTAHFXNGKF-UHFFFAOYSA-N 2-[(2,5-dimethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=C(OC)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 ZQVATTAHFXNGKF-UHFFFAOYSA-N 0.000 claims description 3
- VPTFFYNHFALUCC-UHFFFAOYSA-N 2-[1-(2-methoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC=C1C(C)OC1=CN=CC(N2CCNCC2)=N1 VPTFFYNHFALUCC-UHFFFAOYSA-N 0.000 claims description 3
- LALFVUJPHIMHMK-UHFFFAOYSA-N 2-[2-(2,5-dimethoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=C(OC)C(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1 LALFVUJPHIMHMK-UHFFFAOYSA-N 0.000 claims description 3
- WKSVBLNPKMLRHD-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound FC1=CC=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 WKSVBLNPKMLRHD-UHFFFAOYSA-N 0.000 claims description 3
- FCVRQVXLAUUCFD-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 FCVRQVXLAUUCFD-UHFFFAOYSA-N 0.000 claims description 3
- LWTBOAFHBJYIAK-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=CC(OC)=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 LWTBOAFHBJYIAK-UHFFFAOYSA-N 0.000 claims description 3
- RQBCVNKTVFSCKQ-UHFFFAOYSA-N 2-[2-(7-methoxynaphthalen-2-yl)oxyethoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C2=CC(OC)=CC=C2C=CC=1OCCOC(N=1)=CN=CC=1N1CCNCC1 RQBCVNKTVFSCKQ-UHFFFAOYSA-N 0.000 claims description 3
- SPMYYXYKUSTBMI-UHFFFAOYSA-N 2-[[2-(2-phenylethyl)phenyl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1CCC1=CC=CC=C1COC(N=1)=CN=CC=1N1CCNCC1 SPMYYXYKUSTBMI-UHFFFAOYSA-N 0.000 claims description 3
- OMMBWIWJPLKNFD-UHFFFAOYSA-N 2-phenylmethoxy-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1COC(N=1)=CN=CC=1N1CCNCC1 OMMBWIWJPLKNFD-UHFFFAOYSA-N 0.000 claims description 3
- PIPQCNRCBHVBNI-UHFFFAOYSA-N 3-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethyl]-1h-indole Chemical compound C=1NC2=CC=CC=C2C=1CCOC(N=1)=CN=CC=1N1CCNCC1 PIPQCNRCBHVBNI-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- XIEQLUARAUTYHZ-UHFFFAOYSA-N n,n-dimethyl-4-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethyl]aniline Chemical compound C1=CC(N(C)C)=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 XIEQLUARAUTYHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- OVNQCQYFAZPDCM-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-ylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C1CC2=CC=CC=C2C1COC(N=1)=CN=CC=1N1CCNCC1 OVNQCQYFAZPDCM-UHFFFAOYSA-N 0.000 claims description 2
- DMDFGYIKOXFBAV-UHFFFAOYSA-N 2-(2-ethylpiperazin-1-yl)-6-phenylmethoxypyrazine Chemical compound CCC1CNCCN1C1=CN=CC(OCC=2C=CC=CC=2)=N1 DMDFGYIKOXFBAV-UHFFFAOYSA-N 0.000 claims description 2
- HSLQBXHVDRKYOM-UHFFFAOYSA-N 2-(2-methylpiperazin-1-yl)-6-phenylmethoxypyrazine Chemical compound CC1CNCCN1C1=CN=CC(OCC=2C=CC=CC=2)=N1 HSLQBXHVDRKYOM-UHFFFAOYSA-N 0.000 claims description 2
- KFQAFBLQNMBHQA-UHFFFAOYSA-N 2-(3-naphthalen-2-yloxypropoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=C2C=CC=CC2=CC=1OCCCOC(N=1)=CN=CC=1N1CCNCC1 KFQAFBLQNMBHQA-UHFFFAOYSA-N 0.000 claims description 2
- QJJPYWNZRKAZDM-KGLIPLIRSA-N 2-[(2s,5r)-2,5-dimethylpiperazin-1-yl]-6-phenylmethoxypyrazine Chemical compound C[C@H]1CN[C@H](C)CN1C1=CN=CC(OCC=2C=CC=CC=2)=N1 QJJPYWNZRKAZDM-KGLIPLIRSA-N 0.000 claims description 2
- GMBHDVADYGOKQJ-UHFFFAOYSA-N 2-[(5-fluoro-2-methoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=C(F)C=C1COC1=CN=CC(N2CCNCC2)=N1 GMBHDVADYGOKQJ-UHFFFAOYSA-N 0.000 claims description 2
- QMMYOJDSVCRMCE-UHFFFAOYSA-N 2-[1-(2,6-difluorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound FC=1C=CC=C(F)C=1C(C)OC(N=1)=CN=CC=1N1CCNCC1 QMMYOJDSVCRMCE-UHFFFAOYSA-N 0.000 claims description 2
- UXACGMNLBLFPQV-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound ClC1=CC=CC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1 UXACGMNLBLFPQV-UHFFFAOYSA-N 0.000 claims description 2
- YYWATUWCINOWOO-UHFFFAOYSA-N 2-[[5-(4-chlorophenyl)-2-methylfuran-3-yl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound CC=1OC(C=2C=CC(Cl)=CC=2)=CC=1COC(N=1)=CN=CC=1N1CCNCC1 YYWATUWCINOWOO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- JDVLFAOIOOISOZ-UHFFFAOYSA-N 4-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]-1h-indole Chemical compound C=1C=CC=2NC=CC=2C=1COC(N=1)=CN=CC=1N1CCNCC1 JDVLFAOIOOISOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- APOVIXFCVJIIQD-UHFFFAOYSA-N 5-methyl-2-phenyl-4-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethyl]-1,3-oxazole Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(N=1)=CN=CC=1N1CCNCC1 APOVIXFCVJIIQD-UHFFFAOYSA-N 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005972 dihydrochromenyl group Chemical group 0.000 claims description 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 171
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 149
- 238000000034 method Methods 0.000 description 148
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- 239000003921 oil Substances 0.000 description 95
- 235000019198 oils Nutrition 0.000 description 95
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 91
- 239000000203 mixture Substances 0.000 description 77
- 238000004128 high performance liquid chromatography Methods 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 65
- 239000012458 free base Substances 0.000 description 59
- 239000011541 reaction mixture Substances 0.000 description 58
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 57
- 239000003480 eluent Substances 0.000 description 57
- 229910052799 carbon Inorganic materials 0.000 description 56
- 239000000047 product Substances 0.000 description 55
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 43
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- 229910001868 water Inorganic materials 0.000 description 38
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 238000001914 filtration Methods 0.000 description 32
- 239000012634 fragment Substances 0.000 description 30
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 29
- 150000002688 maleic acid derivatives Chemical class 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 28
- CJAWPFJGFFNXQI-UHFFFAOYSA-N 2-chloro-6-(1-piperazinyl)pyrazine Chemical compound ClC1=CN=CC(N2CCNCC2)=N1 CJAWPFJGFFNXQI-UHFFFAOYSA-N 0.000 description 27
- 239000007858 starting material Substances 0.000 description 27
- 150000001242 acetic acid derivatives Chemical class 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 25
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- 235000015320 potassium carbonate Nutrition 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 15
- 235000011087 fumaric acid Nutrition 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 239000005297 pyrex Substances 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 235000019445 benzyl alcohol Nutrition 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000018 receptor agonist Substances 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000000862 serotonergic effect Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- AFKLSWIRJUJWKY-UHFFFAOYSA-N (3-phenylmethoxyphenyl)methanol Chemical compound OCC1=CC=CC(OCC=2C=CC=CC=2)=C1 AFKLSWIRJUJWKY-UHFFFAOYSA-N 0.000 description 3
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 3
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 101100167280 Caenorhabditis elegans cin-4 gene Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000004885 piperazines Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- WYLYBQSHRJMURN-UHFFFAOYSA-N (2-methoxyphenyl)methanol Chemical compound COC1=CC=CC=C1CO WYLYBQSHRJMURN-UHFFFAOYSA-N 0.000 description 2
- KGANAERDZBAECK-UHFFFAOYSA-N (3-phenoxyphenyl)methanol Chemical compound OCC1=CC=CC(OC=2C=CC=CC=2)=C1 KGANAERDZBAECK-UHFFFAOYSA-N 0.000 description 2
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 2
- BVSGXWCTWBZFEV-UHFFFAOYSA-N 1h-indol-4-ylmethanol Chemical compound OCC1=CC=CC2=C1C=CN2 BVSGXWCTWBZFEV-UHFFFAOYSA-N 0.000 description 2
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 2
- NHCHCNNOCLPGAN-UHFFFAOYSA-N 2-(1-benzothiophen-3-ylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1SC2=CC=CC=C2C=1COC(N=1)=CN=CC=1N1CCNCC1 NHCHCNNOCLPGAN-UHFFFAOYSA-N 0.000 description 2
- PGRIEDZTHGCBCC-UHFFFAOYSA-N 2-(2-naphthalen-2-yloxyethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=C2C=CC=CC2=CC=1OCCOC(N=1)=CN=CC=1N1CCNCC1 PGRIEDZTHGCBCC-UHFFFAOYSA-N 0.000 description 2
- UPPGEJSCUZMCMW-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC(CCO)=C1 UPPGEJSCUZMCMW-UHFFFAOYSA-N 0.000 description 2
- AUWDOZOUJWEPBA-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1 AUWDOZOUJWEPBA-UHFFFAOYSA-N 0.000 description 2
- MXOUZXWXBLATNK-UHFFFAOYSA-N 2-(6-methoxynaphthalen-2-yl)oxyethanol Chemical compound C1=C(OCCO)C=CC2=CC(OC)=CC=C21 MXOUZXWXBLATNK-UHFFFAOYSA-N 0.000 description 2
- MVBQUQYCMNJOAN-UHFFFAOYSA-N 2-(7-methoxynaphthalen-2-yl)oxyethanol Chemical compound C1=CC(OCCO)=CC2=CC(OC)=CC=C21 MVBQUQYCMNJOAN-UHFFFAOYSA-N 0.000 description 2
- URXRQTDMSPIGDN-UHFFFAOYSA-N 2-(naphthalen-2-ylmethoxy)-4-piperazin-1-ylpyrimidine Chemical compound C=1C=C2C=CC=CC2=CC=1COC(N=1)=NC=CC=1N1CCNCC1 URXRQTDMSPIGDN-UHFFFAOYSA-N 0.000 description 2
- LBXPCVSYZSEMJR-UHFFFAOYSA-N 2-[(3,5-dimethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC(OC)=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 LBXPCVSYZSEMJR-UHFFFAOYSA-N 0.000 description 2
- IKPKXZLWJNSWTR-UHFFFAOYSA-N 2-[(3-phenylmethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1COC(N=1)=CN=CC=1N1CCNCC1 IKPKXZLWJNSWTR-UHFFFAOYSA-N 0.000 description 2
- PSPYADOPSPPLBY-UHFFFAOYSA-N 2-[2-(2,6-difluorophenoxy)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound FC1=CC=CC(F)=C1OCCOC1=CN=CC(N2CCNCC2)=N1 PSPYADOPSPPLBY-UHFFFAOYSA-N 0.000 description 2
- LMVCGOMXWHZJLN-SSDOTTSWSA-N 2-chloro-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical compound C[C@@H]1CNCCN1C1=CN=CC(Cl)=N1 LMVCGOMXWHZJLN-SSDOTTSWSA-N 0.000 description 2
- IIKSLMTZLGHLPV-UHFFFAOYSA-N 2-isoquinolin-7-yloxyethanol Chemical compound C1=CN=CC2=CC(OCCO)=CC=C21 IIKSLMTZLGHLPV-UHFFFAOYSA-N 0.000 description 2
- BAVRHUHJDZTNHJ-UHFFFAOYSA-N 2-piperazin-1-yl-6-(pyridin-3-ylmethoxy)pyrazine Chemical compound C=1C=CN=CC=1COC(N=1)=CN=CC=1N1CCNCC1 BAVRHUHJDZTNHJ-UHFFFAOYSA-N 0.000 description 2
- RAEQXHULDSJJES-UHFFFAOYSA-N 2-piperazin-1-yl-6-thiophen-3-ylpyrazine Chemical compound C1CNCCN1C1=CN=CC(C2=CSC=C2)=N1 RAEQXHULDSJJES-UHFFFAOYSA-N 0.000 description 2
- IIGNZLVHOZEOPV-UHFFFAOYSA-N 3-Methoxybenzyl alcohol Chemical compound COC1=CC=CC(CO)=C1 IIGNZLVHOZEOPV-UHFFFAOYSA-N 0.000 description 2
- AWVDYRFLCAZENH-UHFFFAOYSA-N 3-phenoxypropan-1-ol Chemical compound OCCCOC1=CC=CC=C1 AWVDYRFLCAZENH-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- XTZNCVSCVHTPAI-UHFFFAOYSA-N Salmeterol xinafoate Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006642 detritylation reaction Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 102000045993 human HTR2C Human genes 0.000 description 2
- 150000002473 indoazoles Chemical class 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- RWTQYGUCVRJWLC-UHFFFAOYSA-N n-propan-2-yl-4-[3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl]benzamide Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1N1C(CCCC2)=C2C(C(F)(F)F)=N1 RWTQYGUCVRJWLC-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 2
- MBBOMCVGYCRMEA-UHFFFAOYSA-N tryptophol Chemical compound C1=CC=C2C(CCO)=CNC2=C1 MBBOMCVGYCRMEA-UHFFFAOYSA-N 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- PBLNHHSDYFYZNC-UHFFFAOYSA-N (1-naphthyl)methanol Chemical compound C1=CC=C2C(CO)=CC=CC2=C1 PBLNHHSDYFYZNC-UHFFFAOYSA-N 0.000 description 1
- CRLBBOBKCLYCJK-UHFFFAOYSA-N (2,3-dimethoxyphenyl)methanol Chemical compound COC1=CC=CC(CO)=C1OC CRLBBOBKCLYCJK-UHFFFAOYSA-N 0.000 description 1
- KIKCAPPVFQLOIU-UHFFFAOYSA-N (2,5-difluorophenyl)methanol Chemical compound OCC1=CC(F)=CC=C1F KIKCAPPVFQLOIU-UHFFFAOYSA-N 0.000 description 1
- WGQMUABRZGUAOS-UHFFFAOYSA-N (2,5-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(OC)C(CO)=C1 WGQMUABRZGUAOS-UHFFFAOYSA-N 0.000 description 1
- WWFIIZLHSNBNTC-UHFFFAOYSA-N (2-chlorophenyl)methanethiol Chemical compound SCC1=CC=CC=C1Cl WWFIIZLHSNBNTC-UHFFFAOYSA-N 0.000 description 1
- QEHXDOJPVIHUDO-UHFFFAOYSA-N (2-fluorophenyl)methanol Chemical compound OCC1=CC=CC=C1F QEHXDOJPVIHUDO-UHFFFAOYSA-N 0.000 description 1
- VMZBMTWFHYYOIN-UHFFFAOYSA-N (2-phenoxyphenyl)methanol Chemical compound OCC1=CC=CC=C1OC1=CC=CC=C1 VMZBMTWFHYYOIN-UHFFFAOYSA-N 0.000 description 1
- XQTMXUWJPKIPBL-CQSZACIVSA-N (2r)-2-methyl-1-(6-phenylmethoxypyridin-2-yl)piperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(OCC=2C=CC=CC=2)=N1 XQTMXUWJPKIPBL-CQSZACIVSA-N 0.000 description 1
- SZNMZXGTURIXHH-CYBMUJFWSA-N (2r)-2-methyl-1-[6-phenylmethoxy-4-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC(OCC=2C=CC=CC=2)=N1 SZNMZXGTURIXHH-CYBMUJFWSA-N 0.000 description 1
- NSMWYRLQHIXVAP-OLQVQODUSA-N (2r,5s)-2,5-dimethylpiperazine Chemical compound C[C@H]1CN[C@H](C)CN1 NSMWYRLQHIXVAP-OLQVQODUSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-YFKPBYRVSA-N (2s)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1 JOMNTHCQHJPVAZ-YFKPBYRVSA-N 0.000 description 1
- LOGIHEKXJKHXEC-UHFFFAOYSA-N (3,5-difluorophenyl)methanol Chemical compound OCC1=CC(F)=CC(F)=C1 LOGIHEKXJKHXEC-UHFFFAOYSA-N 0.000 description 1
- AUDBREYGQOXIFT-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC(OC)=C1 AUDBREYGQOXIFT-UHFFFAOYSA-N 0.000 description 1
- NEOWWJVXDHGUFW-UHFFFAOYSA-N (3-phenoxythiophen-2-yl)methanol Chemical compound S1C=CC(OC=2C=CC=CC=2)=C1CO NEOWWJVXDHGUFW-UHFFFAOYSA-N 0.000 description 1
- SMSUHWYHSLZKHS-UHFFFAOYSA-N (3-pyrrol-1-ylthiophen-2-yl)methanol Chemical compound S1C=CC(N2C=CC=C2)=C1CO SMSUHWYHSLZKHS-UHFFFAOYSA-N 0.000 description 1
- VYUQPZHRDKLOPX-HXUWFJFHSA-N (3r)-3-methyl-1-tritylpiperazine Chemical compound C1CN[C@H](C)CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VYUQPZHRDKLOPX-HXUWFJFHSA-N 0.000 description 1
- VYUQPZHRDKLOPX-FQEVSTJZSA-N (3s)-3-methyl-1-tritylpiperazine Chemical compound C1CN[C@@H](C)CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VYUQPZHRDKLOPX-FQEVSTJZSA-N 0.000 description 1
- FEOMFFKZOZMBKD-UHFFFAOYSA-N (4-phenoxyphenyl)methanol Chemical compound C1=CC(CO)=CC=C1OC1=CC=CC=C1 FEOMFFKZOZMBKD-UHFFFAOYSA-N 0.000 description 1
- AXCHZLOJGKSWLV-UHFFFAOYSA-N (4-phenylphenyl)methanol Chemical compound C1=CC(CO)=CC=C1C1=CC=CC=C1 AXCHZLOJGKSWLV-UHFFFAOYSA-N 0.000 description 1
- BESAKUXOHCFPAA-UHFFFAOYSA-N (4-pyridin-2-ylphenyl)methanol Chemical compound C1=CC(CO)=CC=C1C1=CC=CC=N1 BESAKUXOHCFPAA-UHFFFAOYSA-N 0.000 description 1
- NJDNHGOIOZXFCB-UHFFFAOYSA-N (5-fluoro-2-methoxyphenyl)methanol Chemical compound COC1=CC=C(F)C=C1CO NJDNHGOIOZXFCB-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-dioxonaphthalene Natural products C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- LFWCEWLQBGZAGG-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)piperazine Chemical class C1CNCCN1C1=CC2=CC=CC=C2O1 LFWCEWLQBGZAGG-UHFFFAOYSA-N 0.000 description 1
- QUERAHCHJWZYJF-UHFFFAOYSA-N 1-(1h-indol-2-yl)ethanamine Chemical class C1=CC=C2NC(C(N)C)=CC2=C1 QUERAHCHJWZYJF-UHFFFAOYSA-N 0.000 description 1
- SIYWDKQSSDBLOA-UHFFFAOYSA-N 1-(2,6-difluorophenyl)ethanol Chemical compound CC(O)C1=C(F)C=CC=C1F SIYWDKQSSDBLOA-UHFFFAOYSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical class C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- DHHGVIOVURMJEA-UHFFFAOYSA-N 1-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1C(C)O DHHGVIOVURMJEA-UHFFFAOYSA-N 0.000 description 1
- YESOPGLEIJQAEF-UHFFFAOYSA-N 1-(3-fluorophenyl)ethanol Chemical compound CC(O)C1=CC=CC(F)=C1 YESOPGLEIJQAEF-UHFFFAOYSA-N 0.000 description 1
- TWHZQGKJLIPNKC-UHFFFAOYSA-N 1-(6-butylsulfanylpyridin-2-yl)piperazine Chemical compound CCCCSC1=CC=CC(N2CCNCC2)=N1 TWHZQGKJLIPNKC-UHFFFAOYSA-N 0.000 description 1
- CGVOTFHOTLOYKI-UHFFFAOYSA-N 1-(6-chloropyridin-2-yl)-3-methylpiperazine Chemical compound C1CNC(C)CN1C1=CC=CC(Cl)=N1 CGVOTFHOTLOYKI-UHFFFAOYSA-N 0.000 description 1
- OOMBBUZQJGYRRW-UHFFFAOYSA-N 1-(6-chloropyridin-2-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC(Cl)=N1 OOMBBUZQJGYRRW-UHFFFAOYSA-N 0.000 description 1
- WWCAWWWQVWKEPB-UHFFFAOYSA-N 1-(6-cyclobutyloxypyridin-2-yl)piperazine Chemical compound C1CCC1OC1=CC=CC(N2CCNCC2)=N1 WWCAWWWQVWKEPB-UHFFFAOYSA-N 0.000 description 1
- VMZQHLNODJSPHO-UHFFFAOYSA-N 1-(6-cyclohexyloxypyridin-2-yl)piperazine Chemical compound C1CCCCC1OC1=CC=CC(N2CCNCC2)=N1 VMZQHLNODJSPHO-UHFFFAOYSA-N 0.000 description 1
- YIKODFMBXXQGIK-UHFFFAOYSA-N 1-(6-cyclopentyloxypyridin-2-yl)piperazine Chemical compound C1CCCC1OC1=CC=CC(N2CCNCC2)=N1 YIKODFMBXXQGIK-UHFFFAOYSA-N 0.000 description 1
- COLGTEXTAQAQGH-UHFFFAOYSA-N 1-(6-phenylmethoxypyridin-2-yl)piperazine Chemical compound C=1C=CC=CC=1COC(N=1)=CC=CC=1N1CCNCC1 COLGTEXTAQAQGH-UHFFFAOYSA-N 0.000 description 1
- FTLURDYNTODIEK-UHFFFAOYSA-N 1-[6-(2-methylpropoxy)pyridin-2-yl]piperazine Chemical compound CC(C)COC1=CC=CC(N2CCNCC2)=N1 FTLURDYNTODIEK-UHFFFAOYSA-N 0.000 description 1
- RVYSFDSBHGXYDX-UHFFFAOYSA-N 1-[6-(cyclohexylmethyl)pyridin-2-yl]piperazine Chemical compound C=1C=CC(N2CCNCC2)=NC=1CC1CCCCC1 RVYSFDSBHGXYDX-UHFFFAOYSA-N 0.000 description 1
- ZEEQFFNXWAZADS-UHFFFAOYSA-N 1-[6-(cyclopropylmethoxy)pyridin-2-yl]piperazine Chemical compound C1CC1COC(N=1)=CC=CC=1N1CCNCC1 ZEEQFFNXWAZADS-UHFFFAOYSA-N 0.000 description 1
- OVHUQEKUGULMIR-UHFFFAOYSA-N 1-[6-(thiophen-2-ylmethoxy)pyridin-2-yl]piperazine Chemical compound C=1C=CSC=1COC(N=1)=CC=CC=1N1CCNCC1 OVHUQEKUGULMIR-UHFFFAOYSA-N 0.000 description 1
- HSOMHPHYGAQRTF-UHFFFAOYSA-N 1-benzofuran-2-ylmethanol Chemical compound C1=CC=C2OC(CO)=CC2=C1 HSOMHPHYGAQRTF-UHFFFAOYSA-N 0.000 description 1
- UYGMKSKKGSUAHB-UHFFFAOYSA-N 1-benzothiophen-3-ylmethanol Chemical compound C1=CC=C2C(CO)=CSC2=C1 UYGMKSKKGSUAHB-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- CTPKPBTULPZITK-UHFFFAOYSA-N 1-benzyl-3-ethylpiperazine Chemical compound C1CNC(CC)CN1CC1=CC=CC=C1 CTPKPBTULPZITK-UHFFFAOYSA-N 0.000 description 1
- WPCMSUSLCWXTKB-UHFFFAOYSA-N 1-cyclopentylethanol Chemical compound CC(O)C1CCCC1 WPCMSUSLCWXTKB-UHFFFAOYSA-N 0.000 description 1
- DKKVKJZXOBFLRY-UHFFFAOYSA-N 1-cyclopropylethanol Chemical compound CC(O)C1CC1 DKKVKJZXOBFLRY-UHFFFAOYSA-N 0.000 description 1
- 125000004345 1-phenyl-2-propyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WYTRYIUQUDTGSX-UHFFFAOYSA-N 1-phenylpropan-2-ol Chemical compound CC(O)CC1=CC=CC=C1 WYTRYIUQUDTGSX-UHFFFAOYSA-N 0.000 description 1
- IVCGJOSPVGENCT-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinoline Chemical class N1=CC=CC2=C(NC=C3)C3=CC=C21 IVCGJOSPVGENCT-UHFFFAOYSA-N 0.000 description 1
- PIPWSBOFSUJCCO-UHFFFAOYSA-N 2,2-dimethylpiperazine Chemical compound CC1(C)CNCCN1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
- FFLHNBGNAWYMRH-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-ylmethanol Chemical compound O1CCOC2=CC(CO)=CC=C21 FFLHNBGNAWYMRH-UHFFFAOYSA-N 0.000 description 1
- KMGCKSAIIHOKCX-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2CC(O)CC2=C1 KMGCKSAIIHOKCX-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- KVNQWVYYVLCZKK-UHFFFAOYSA-N 2,6-dichloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(Cl)=NC(Cl)=C1 KVNQWVYYVLCZKK-UHFFFAOYSA-N 0.000 description 1
- GRFCSKLMYBQFFA-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylmethoxy)-6-chloropyrazine Chemical compound ClC1=CN=CC(OCC=2C=C3OCOC3=CC=2)=N1 GRFCSKLMYBQFFA-UHFFFAOYSA-N 0.000 description 1
- ZZBROSOVVCWJEU-UHFFFAOYSA-N 2-(1-benzofuran-2-ylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C2=CC=CC=C2OC=1COC(N=1)=CN=CC=1N1CCNCC1 ZZBROSOVVCWJEU-UHFFFAOYSA-N 0.000 description 1
- GEXSCNSEWFMFAP-UHFFFAOYSA-N 2-(1-benzothiophen-3-ylmethoxy)-6-chloropyrazine Chemical compound ClC1=CN=CC(OCC=2C3=CC=CC=C3SC=2)=N1 GEXSCNSEWFMFAP-UHFFFAOYSA-N 0.000 description 1
- LZSSZBUCKKHTCI-UHFFFAOYSA-N 2-(1-cyclopentylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C1CCCC1C(C)OC(N=1)=CN=CC=1N1CCNCC1 LZSSZBUCKKHTCI-UHFFFAOYSA-N 0.000 description 1
- WUBNMTBWOPEPRP-UHFFFAOYSA-N 2-(1-cyclopropylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C1CC1C(C)OC(N=1)=CN=CC=1N1CCNCC1 WUBNMTBWOPEPRP-UHFFFAOYSA-N 0.000 description 1
- BFOWHMGSWBDAOH-UHFFFAOYSA-N 2-(1-phenylpropan-2-yloxy)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OC(C)CC1=CC=CC=C1 BFOWHMGSWBDAOH-UHFFFAOYSA-N 0.000 description 1
- CLTXDHUACHRMNT-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-ylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=C2OCCOC2=CC=1COC(N=1)=CN=CC=1N1CCNCC1 CLTXDHUACHRMNT-UHFFFAOYSA-N 0.000 description 1
- IYOLOWVCYMYFRQ-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yloxy)-6-piperazin-1-ylpyrazine Chemical compound C1C2=CC=CC=C2CC1OC(N=1)=CN=CC=1N1CCNCC1 IYOLOWVCYMYFRQ-UHFFFAOYSA-N 0.000 description 1
- WKWPWEFKXHIZNO-UHFFFAOYSA-N 2-(2,3-dimethoxyphenyl)ethanol Chemical compound COC1=CC=CC(CCO)=C1OC WKWPWEFKXHIZNO-UHFFFAOYSA-N 0.000 description 1
- BBZDYQUXRFATHZ-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=C(OC)C(CC(O)=O)=C1 BBZDYQUXRFATHZ-UHFFFAOYSA-N 0.000 description 1
- DJYVHWLFFMIWOY-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)ethanol Chemical compound COC1=CC=C(OC)C(CCO)=C1 DJYVHWLFFMIWOY-UHFFFAOYSA-N 0.000 description 1
- XFUAUOPYQQCXLZ-UHFFFAOYSA-N 2-(2,6-difluorophenoxy)ethanol Chemical compound OCCOC1=C(F)C=CC=C1F XFUAUOPYQQCXLZ-UHFFFAOYSA-N 0.000 description 1
- YRGSJXHFLKEHLF-UHFFFAOYSA-N 2-(2-aminoquinolin-8-yl)oxyethanol Chemical compound C1=CC=C(OCCO)C2=NC(N)=CC=C21 YRGSJXHFLKEHLF-UHFFFAOYSA-N 0.000 description 1
- XAICVUKTRSTLGS-UHFFFAOYSA-N 2-(2-cyclohexylethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCC1CCCCC1 XAICVUKTRSTLGS-UHFFFAOYSA-N 0.000 description 1
- UDWGWYLEOMBXHW-UHFFFAOYSA-N 2-(2-ethoxypyridin-3-yl)oxyethanol Chemical compound CCOC1=NC=CC=C1OCCO UDWGWYLEOMBXHW-UHFFFAOYSA-N 0.000 description 1
- FORZJPUYXNNFMZ-UHFFFAOYSA-N 2-(2-fluoroethoxy)-6-piperazin-1-ylpyrazine Chemical compound FCCOC1=CN=CC(N2CCNCC2)=N1 FORZJPUYXNNFMZ-UHFFFAOYSA-N 0.000 description 1
- HNIGZVZDWCTFPR-UHFFFAOYSA-N 2-(2-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC=C1F HNIGZVZDWCTFPR-UHFFFAOYSA-N 0.000 description 1
- XLDRDNQLEMMNNH-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1CCO XLDRDNQLEMMNNH-UHFFFAOYSA-N 0.000 description 1
- AIQOYAMVNHWZRX-UHFFFAOYSA-N 2-(2-phenoxyethoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1OCCOC(N=1)=CN=CC=1N1CCNCC1 AIQOYAMVNHWZRX-UHFFFAOYSA-N 0.000 description 1
- CMULHUWCYRHYBR-UHFFFAOYSA-N 2-(2-phenylethoxy)-6-piperidin-4-yloxypyrazine Chemical compound C=1N=CC(OC2CCNCC2)=NC=1OCCC1=CC=CC=C1 CMULHUWCYRHYBR-UHFFFAOYSA-N 0.000 description 1
- VFYKRBZHJFJOGQ-UHFFFAOYSA-N 2-(2-phenylmethoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1OCC1=CC=CC=C1 VFYKRBZHJFJOGQ-UHFFFAOYSA-N 0.000 description 1
- KAMXYCVETYXNSB-UHFFFAOYSA-N 2-(2-phenylmethoxyphenyl)ethanol Chemical compound OCCC1=CC=CC=C1OCC1=CC=CC=C1 KAMXYCVETYXNSB-UHFFFAOYSA-N 0.000 description 1
- WPOCCKRGOFTKAE-UHFFFAOYSA-N 2-(2-phenylpropoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1C(C)COC(N=1)=CN=CC=1N1CCNCC1 WPOCCKRGOFTKAE-UHFFFAOYSA-N 0.000 description 1
- SRQAJMUHZROVHW-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1OC SRQAJMUHZROVHW-UHFFFAOYSA-N 0.000 description 1
- OCYJPLKMOFYULY-UHFFFAOYSA-N 2-(3-bromophenyl)-4-piperazin-1-ylpyrimidine Chemical compound BrC1=CC=CC(C=2N=C(C=CN=2)N2CCNCC2)=C1 OCYJPLKMOFYULY-UHFFFAOYSA-N 0.000 description 1
- NDWAVJKRSASRPH-UHFFFAOYSA-N 2-(3-chlorophenyl)ethanol Chemical compound OCCC1=CC=CC(Cl)=C1 NDWAVJKRSASRPH-UHFFFAOYSA-N 0.000 description 1
- YBPWQIZOHQGENF-UHFFFAOYSA-N 2-(3-methoxyphenoxy)ethanol Chemical compound COC1=CC=CC(OCCO)=C1 YBPWQIZOHQGENF-UHFFFAOYSA-N 0.000 description 1
- GTFJVXFKDWKCKU-UHFFFAOYSA-N 2-(3-phenoxypropoxy)-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCCOC1=CC=CC=C1 GTFJVXFKDWKCKU-UHFFFAOYSA-N 0.000 description 1
- XRTNTWXWSWZWIL-UHFFFAOYSA-N 2-(3-phenoxypropoxy)-6-piperidin-4-yloxypyrazine Chemical compound C=1N=CC(OC2CCNCC2)=NC=1OCCCOC1=CC=CC=C1 XRTNTWXWSWZWIL-UHFFFAOYSA-N 0.000 description 1
- JYWHQBLLIBQGCU-UHFFFAOYSA-N 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethanol Chemical compound OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 JYWHQBLLIBQGCU-UHFFFAOYSA-N 0.000 description 1
- JOFZNTNUKIUFQJ-UHFFFAOYSA-N 2-(5-nitrofuran-2-yl)pyrimidine Chemical class O1C([N+](=O)[O-])=CC=C1C1=NC=CC=N1 JOFZNTNUKIUFQJ-UHFFFAOYSA-N 0.000 description 1
- GQIOSHKNGBSHHB-UHFFFAOYSA-N 2-(5-phenylpentoxy)-6-piperidin-4-yloxypyrazine Chemical compound C=1C=CC=CC=1CCCCCOC(N=1)=CN=CC=1OC1CCNCC1 GQIOSHKNGBSHHB-UHFFFAOYSA-N 0.000 description 1
- QJAAZEODBJHOIE-UHFFFAOYSA-N 2-(cyclopentylmethoxy)-6-piperazin-1-ylpyrazine Chemical compound C1CCCC1COC(N=1)=CN=CC=1N1CCNCC1 QJAAZEODBJHOIE-UHFFFAOYSA-N 0.000 description 1
- PFEJKGAHWBIOQQ-UHFFFAOYSA-N 2-(furan-2-yl)-6-piperazin-1-ylpyrazine Chemical compound C1CNCCN1C1=CN=CC(C=2OC=CC=2)=N1 PFEJKGAHWBIOQQ-UHFFFAOYSA-N 0.000 description 1
- YKNORODREYVARM-UHFFFAOYSA-N 2-(phenoxymethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=CC=C1 YKNORODREYVARM-UHFFFAOYSA-N 0.000 description 1
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VSXCPAAIVRSIGV-UHFFFAOYSA-N 2-[(2,3-dimethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1OC VSXCPAAIVRSIGV-UHFFFAOYSA-N 0.000 description 1
- RNWQKUXWKDGPTF-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound FC1=CC=C(F)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 RNWQKUXWKDGPTF-UHFFFAOYSA-N 0.000 description 1
- KFSIBDILKOCDLE-UHFFFAOYSA-N 2-[(2-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound FC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 KFSIBDILKOCDLE-UHFFFAOYSA-N 0.000 description 1
- HSLQBXHVDRKYOM-CYBMUJFWSA-N 2-[(2r)-2-methylpiperazin-1-yl]-6-phenylmethoxypyrazine Chemical compound C[C@@H]1CNCCN1C1=CN=CC(OCC=2C=CC=CC=2)=N1 HSLQBXHVDRKYOM-CYBMUJFWSA-N 0.000 description 1
- HSLQBXHVDRKYOM-ZDUSSCGKSA-N 2-[(2s)-2-methylpiperazin-1-yl]-6-phenylmethoxypyrazine Chemical compound C[C@H]1CNCCN1C1=CN=CC(OCC=2C=CC=CC=2)=N1 HSLQBXHVDRKYOM-ZDUSSCGKSA-N 0.000 description 1
- FPYRELXMMFMFCR-UHFFFAOYSA-N 2-[(3-methoxy-4-phenylmethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(OC)=CC=1COC(N=1)=CN=CC=1N1CCNCC1 FPYRELXMMFMFCR-UHFFFAOYSA-N 0.000 description 1
- COQKRZUTHFXRJV-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 COQKRZUTHFXRJV-UHFFFAOYSA-N 0.000 description 1
- XZEUVSFATDGCOA-UHFFFAOYSA-N 2-[(3-phenoxythiophen-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound S1C=CC(OC=2C=CC=CC=2)=C1COC(N=1)=CN=CC=1N1CCNCC1 XZEUVSFATDGCOA-UHFFFAOYSA-N 0.000 description 1
- VJLGIEQGTPOULD-UHFFFAOYSA-N 2-[(3-phenylmethoxyphenyl)methoxy]-6-piperidin-4-yloxypyrazine Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1COC(N=1)=CN=CC=1OC1CCNCC1 VJLGIEQGTPOULD-UHFFFAOYSA-N 0.000 description 1
- HAONRLGFUZVPJM-UHFFFAOYSA-N 2-[(4-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=CC(F)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 HAONRLGFUZVPJM-UHFFFAOYSA-N 0.000 description 1
- JLZKWYXJUNHMAN-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=CC(OC)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 JLZKWYXJUNHMAN-UHFFFAOYSA-N 0.000 description 1
- UBVXLHPDIHFMBO-UHFFFAOYSA-N 2-[(4-phenoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1COC(N=1)=CN=CC=1N1CCNCC1 UBVXLHPDIHFMBO-UHFFFAOYSA-N 0.000 description 1
- LCZJDMMBDYRTBT-UHFFFAOYSA-N 2-[(4-phenylmethoxyphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1COC(C=C1)=CC=C1COC(N=1)=CN=CC=1N1CCNCC1 LCZJDMMBDYRTBT-UHFFFAOYSA-N 0.000 description 1
- AWRUQRNWEHGDDJ-UHFFFAOYSA-N 2-[(4-phenylphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1COC(N=1)=CN=CC=1N1CCNCC1 AWRUQRNWEHGDDJ-UHFFFAOYSA-N 0.000 description 1
- IDIONCMEVDFOCV-UHFFFAOYSA-N 2-[2-(2,3-dimethoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1OC IDIONCMEVDFOCV-UHFFFAOYSA-N 0.000 description 1
- YNRNHWAWKXTTMX-UHFFFAOYSA-N 2-[2-(2-ethoxypyridin-3-yl)oxyethoxy]-6-piperazin-1-ylpyrazine Chemical compound CCOC1=NC=CC=C1OCCOC1=CN=CC(N2CCNCC2)=N1 YNRNHWAWKXTTMX-UHFFFAOYSA-N 0.000 description 1
- APGIEWFQNAAASH-UHFFFAOYSA-N 2-[2-(2-phenylmethoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCC1=CC=CC=C1OCC1=CC=CC=C1 APGIEWFQNAAASH-UHFFFAOYSA-N 0.000 description 1
- UYIOHTUQTPTLNR-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 UYIOHTUQTPTLNR-UHFFFAOYSA-N 0.000 description 1
- JDVFMKOYBZHWKI-UHFFFAOYSA-N 2-[2-(3-methoxyphenoxy)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound COC1=CC=CC(OCCOC=2N=C(C=NC=2)N2CCNCC2)=C1 JDVFMKOYBZHWKI-UHFFFAOYSA-N 0.000 description 1
- XCQXORKOHZFXET-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=CC(F)=CC=C1CCOC1=CN=CC(N2CCNCC2)=N1 XCQXORKOHZFXET-UHFFFAOYSA-N 0.000 description 1
- FVNFSZZWXNDEOW-UHFFFAOYSA-N 2-[2-(6-methoxynaphthalen-2-yl)oxyethoxy]-6-piperazin-1-ylpyrazine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OCCOC(N=1)=CN=CC=1N1CCNCC1 FVNFSZZWXNDEOW-UHFFFAOYSA-N 0.000 description 1
- DAJHIBLFQIGDGN-UHFFFAOYSA-N 2-[2-[3-methoxy-2-(phenoxymethyl)phenyl]ethoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=CC=1OCC=1C(OC)=CC=CC=1CCOC(N=1)=CN=CC=1N1CCNCC1 DAJHIBLFQIGDGN-UHFFFAOYSA-N 0.000 description 1
- LHKBVBVKNLICSW-UHFFFAOYSA-N 2-[4-[2-(5-nitrofuran-2-yl)pyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C1=CC=NC(C=2OC(=CC=2)[N+]([O-])=O)=N1 LHKBVBVKNLICSW-UHFFFAOYSA-N 0.000 description 1
- IXCJTALGVGWKHY-CYBMUJFWSA-N 2-[[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound C([C@@H]1OC2=CC=CC=C2OC1)OC(N=1)=CN=CC=1N1CCNCC1 IXCJTALGVGWKHY-CYBMUJFWSA-N 0.000 description 1
- XICIDTYCVSPYEV-UHFFFAOYSA-N 2-[[2-(phenoxymethyl)phenyl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=CC=C(COC=2N=C(C=NC=2)N2CCNCC2)C=1COC1=CC=CC=C1 XICIDTYCVSPYEV-UHFFFAOYSA-N 0.000 description 1
- LTYFTCDWGHXQEH-UHFFFAOYSA-N 2-[[4-(2-phenylethynyl)thiophen-2-yl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C(C#CC=2C=CC=CC=2)=CSC=1COC(N=1)=CN=CC=1N1CCNCC1 LTYFTCDWGHXQEH-UHFFFAOYSA-N 0.000 description 1
- MLJLGQLNSJKXSV-UHFFFAOYSA-N 2-[[5-(2-phenylethynyl)thiophen-2-yl]methoxy]-6-piperazin-1-ylpyrazine Chemical compound C=1C=C(C#CC=2C=CC=CC=2)SC=1COC(N=1)=CN=CC=1N1CCNCC1 MLJLGQLNSJKXSV-UHFFFAOYSA-N 0.000 description 1
- YMGWSIGLNZOGPL-UHFFFAOYSA-N 2-benzyl-6-piperazin-1-ylpyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1CC1=CC=CC=C1 YMGWSIGLNZOGPL-UHFFFAOYSA-N 0.000 description 1
- SFYYCOYORWAGQC-UHFFFAOYSA-N 2-chloro-4-piperazin-1-ylpyrimidine Chemical compound ClC1=NC=CC(N2CCNCC2)=N1 SFYYCOYORWAGQC-UHFFFAOYSA-N 0.000 description 1
- WRECNVGBZLTWOC-UHFFFAOYSA-N 2-chloro-6-(1-cyclopropylethoxy)pyrazine Chemical compound C1CC1C(C)OC1=CN=CC(Cl)=N1 WRECNVGBZLTWOC-UHFFFAOYSA-N 0.000 description 1
- DUJRCFFKVMPKHT-UHFFFAOYSA-N 2-chloro-6-(2,3-dihydro-1h-inden-1-ylmethoxy)pyrazine Chemical compound ClC1=CN=CC(OCC2C3=CC=CC=C3CC2)=N1 DUJRCFFKVMPKHT-UHFFFAOYSA-N 0.000 description 1
- PUQNXLXPFDMCDZ-UHFFFAOYSA-N 2-chloro-6-(2-fluoroethoxy)pyrazine Chemical compound FCCOC1=CN=CC(Cl)=N1 PUQNXLXPFDMCDZ-UHFFFAOYSA-N 0.000 description 1
- FDGGAALTQOOOST-UHFFFAOYSA-N 2-chloro-6-(2-naphthalen-2-ylethoxy)pyrazine Chemical compound ClC1=CN=CC(OCCC=2C=C3C=CC=CC3=CC=2)=N1 FDGGAALTQOOOST-UHFFFAOYSA-N 0.000 description 1
- QUFUSTDGEFAZLA-UHFFFAOYSA-N 2-chloro-6-(2-phenylpropoxy)pyrazine Chemical compound C=1C=CC=CC=1C(C)COC1=CN=CC(Cl)=N1 QUFUSTDGEFAZLA-UHFFFAOYSA-N 0.000 description 1
- KEJDCBIDKOONOG-UHFFFAOYSA-N 2-chloro-6-(3-naphthalen-2-yloxypropoxy)pyrazine Chemical compound ClC1=CN=CC(OCCCOC=2C=C3C=CC=CC3=CC=2)=N1 KEJDCBIDKOONOG-UHFFFAOYSA-N 0.000 description 1
- WGUHNXNAGWOIJP-UHFFFAOYSA-N 2-chloro-6-(3-phenoxypropoxy)pyrazine Chemical compound ClC1=CN=CC(OCCCOC=2C=CC=CC=2)=N1 WGUHNXNAGWOIJP-UHFFFAOYSA-N 0.000 description 1
- RIUROXADJHIKPQ-UHFFFAOYSA-N 2-chloro-6-(5-phenoxypentoxy)pyrazine Chemical compound ClC1=CN=CC(OCCCCCOC=2C=CC=CC=2)=N1 RIUROXADJHIKPQ-UHFFFAOYSA-N 0.000 description 1
- HJMUEQUXIPWFNC-UHFFFAOYSA-N 2-chloro-6-(thiophen-2-ylmethoxy)pyridine Chemical compound ClC1=CC=CC(OCC=2SC=CC=2)=N1 HJMUEQUXIPWFNC-UHFFFAOYSA-N 0.000 description 1
- FREMNQDNZKJSJN-UHFFFAOYSA-N 2-chloro-6-[(2,3-dimethoxyphenyl)methoxy]pyrazine Chemical compound COC1=CC=CC(COC=2N=C(Cl)C=NC=2)=C1OC FREMNQDNZKJSJN-UHFFFAOYSA-N 0.000 description 1
- PPSNAYIRCJKOOR-UHFFFAOYSA-N 2-chloro-6-[(2,5-difluorophenyl)methoxy]pyrazine Chemical compound FC1=CC=C(F)C(COC=2N=C(Cl)C=NC=2)=C1 PPSNAYIRCJKOOR-UHFFFAOYSA-N 0.000 description 1
- FAJNBEHVJFWDFC-UHFFFAOYSA-N 2-chloro-6-[(2,5-dimethoxyphenyl)methoxy]pyrazine Chemical compound COC1=CC=C(OC)C(COC=2N=C(Cl)C=NC=2)=C1 FAJNBEHVJFWDFC-UHFFFAOYSA-N 0.000 description 1
- CJZNTGHFABWIEZ-UHFFFAOYSA-N 2-chloro-6-[(2-fluorophenyl)methoxy]pyrazine Chemical compound FC1=CC=CC=C1COC1=CN=CC(Cl)=N1 CJZNTGHFABWIEZ-UHFFFAOYSA-N 0.000 description 1
- DONULQWULUWENJ-UHFFFAOYSA-N 2-chloro-6-[(2-methoxyphenyl)methoxy]pyrazine Chemical compound COC1=CC=CC=C1COC1=CN=CC(Cl)=N1 DONULQWULUWENJ-UHFFFAOYSA-N 0.000 description 1
- FUYSZIKQQNNHFL-UHFFFAOYSA-N 2-chloro-6-[(2-phenoxyphenyl)methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2C(=CC=CC=2)OC=2C=CC=CC=2)=N1 FUYSZIKQQNNHFL-UHFFFAOYSA-N 0.000 description 1
- LMVCGOMXWHZJLN-ZETCQYMHSA-N 2-chloro-6-[(2s)-2-methylpiperazin-1-yl]pyrazine Chemical compound C[C@H]1CNCCN1C1=CN=CC(Cl)=N1 LMVCGOMXWHZJLN-ZETCQYMHSA-N 0.000 description 1
- BCMYJEWPANIGFX-UHFFFAOYSA-N 2-chloro-6-[(3-phenoxyphenyl)methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2C=C(OC=3C=CC=CC=3)C=CC=2)=N1 BCMYJEWPANIGFX-UHFFFAOYSA-N 0.000 description 1
- PNAKXXOOBMKSPA-UHFFFAOYSA-N 2-chloro-6-[(3-phenoxythiophen-2-yl)methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC2=C(C=CS2)OC=2C=CC=CC=2)=N1 PNAKXXOOBMKSPA-UHFFFAOYSA-N 0.000 description 1
- LNDGVQSRSUMFIQ-UHFFFAOYSA-N 2-chloro-6-[(4-phenylmethoxyphenyl)methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 LNDGVQSRSUMFIQ-UHFFFAOYSA-N 0.000 description 1
- ACUSCSZAQFVSPS-UHFFFAOYSA-N 2-chloro-6-[(4-pyridin-2-ylphenyl)methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2C=CC(=CC=2)C=2N=CC=CC=2)=N1 ACUSCSZAQFVSPS-UHFFFAOYSA-N 0.000 description 1
- IBAKJDGOPJGBRJ-UHFFFAOYSA-N 2-chloro-6-[2-(2,3-dimethoxyphenyl)ethoxy]pyrazine Chemical compound COC1=CC=CC(CCOC=2N=C(Cl)C=NC=2)=C1OC IBAKJDGOPJGBRJ-UHFFFAOYSA-N 0.000 description 1
- FQOFSBILMQIIJA-UHFFFAOYSA-N 2-chloro-6-[2-(2-fluorophenyl)ethoxy]pyrazine Chemical compound FC1=CC=CC=C1CCOC1=CN=CC(Cl)=N1 FQOFSBILMQIIJA-UHFFFAOYSA-N 0.000 description 1
- IYAMURHMVHIPTK-UHFFFAOYSA-N 2-chloro-6-[2-(2-methoxyphenyl)ethoxy]pyrazine Chemical compound COC1=CC=CC=C1CCOC1=CN=CC(Cl)=N1 IYAMURHMVHIPTK-UHFFFAOYSA-N 0.000 description 1
- LGZGFHGNOCCTLI-UHFFFAOYSA-N 2-chloro-6-[2-(3,4-dimethoxyphenyl)ethoxy]pyrazine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CN=CC(Cl)=N1 LGZGFHGNOCCTLI-UHFFFAOYSA-N 0.000 description 1
- DHQSNMJVCCIZJQ-UHFFFAOYSA-N 2-chloro-6-[2-(3-methoxyphenyl)ethoxy]pyrazine Chemical compound COC1=CC=CC(CCOC=2N=C(Cl)C=NC=2)=C1 DHQSNMJVCCIZJQ-UHFFFAOYSA-N 0.000 description 1
- RXODXAURSQKXAD-UHFFFAOYSA-N 2-chloro-6-[2-(6-methoxynaphthalen-2-yl)oxyethoxy]pyrazine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OCCOC1=CN=CC(Cl)=N1 RXODXAURSQKXAD-UHFFFAOYSA-N 0.000 description 1
- FPHXOJDLHKSBJM-UHFFFAOYSA-N 2-chloro-6-[2-(7-methoxynaphthalen-2-yl)oxyethoxy]pyrazine Chemical compound C=1C2=CC(OC)=CC=C2C=CC=1OCCOC1=CN=CC(Cl)=N1 FPHXOJDLHKSBJM-UHFFFAOYSA-N 0.000 description 1
- UEXRUYUZCNLDSV-UHFFFAOYSA-N 2-chloro-6-[[2-(2-phenylethyl)phenyl]methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2C(=CC=CC=2)CCC=2C=CC=CC=2)=N1 UEXRUYUZCNLDSV-UHFFFAOYSA-N 0.000 description 1
- YNMWKZIYUJYMPH-UHFFFAOYSA-N 2-chloro-6-[[4-(2-phenylethynyl)thiophen-2-yl]methoxy]pyrazine Chemical compound ClC1=CN=CC(OCC=2SC=C(C=2)C#CC=2C=CC=CC=2)=N1 YNMWKZIYUJYMPH-UHFFFAOYSA-N 0.000 description 1
- CAKDSWAHIPSTES-UHFFFAOYSA-N 2-chloro-6-[[5-(4-chlorophenyl)-2-methylfuran-3-yl]methoxy]pyrazine Chemical compound CC=1OC(C=2C=CC(Cl)=CC=2)=CC=1COC1=CN=CC(Cl)=N1 CAKDSWAHIPSTES-UHFFFAOYSA-N 0.000 description 1
- HAUFZHNTPRRIAB-UHFFFAOYSA-N 2-chloro-6-hexoxypyrazine Chemical compound CCCCCCOC1=CN=CC(Cl)=N1 HAUFZHNTPRRIAB-UHFFFAOYSA-N 0.000 description 1
- ILHLIZGFBFJFNN-UHFFFAOYSA-N 2-chloro-6-piperidin-4-yloxypyrazine Chemical compound ClC1=CN=CC(OC2CCNCC2)=N1 ILHLIZGFBFJFNN-UHFFFAOYSA-N 0.000 description 1
- WBVIVIOAWVQYNO-UHFFFAOYSA-N 2-chloro-6-prop-2-ynoxypyrazine Chemical compound ClC1=CN=CC(OCC#C)=N1 WBVIVIOAWVQYNO-UHFFFAOYSA-N 0.000 description 1
- QJQZRLXDLORINA-UHFFFAOYSA-N 2-cyclohexylethanol Chemical compound OCCC1CCCCC1 QJQZRLXDLORINA-UHFFFAOYSA-N 0.000 description 1
- DXOHZOPKNFZZAD-UHFFFAOYSA-N 2-ethylpiperazine Chemical compound CCC1CNCCN1 DXOHZOPKNFZZAD-UHFFFAOYSA-N 0.000 description 1
- GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 1
- RVNABWOSTYKNDL-UHFFFAOYSA-N 2-hexoxy-6-piperazin-1-ylpyrazine Chemical compound CCCCCCOC1=CN=CC(N2CCNCC2)=N1 RVNABWOSTYKNDL-UHFFFAOYSA-N 0.000 description 1
- XDOFKUHHLNYRPM-UHFFFAOYSA-N 2-hydroxypiperidine-1-carboxylic acid Chemical compound OC1CCCCN1C(O)=O XDOFKUHHLNYRPM-UHFFFAOYSA-N 0.000 description 1
- MWUVMGYIPOWLAH-UHFFFAOYSA-N 2-indol-1-ylethanol Chemical compound C1=CC=C2N(CCO)C=CC2=C1 MWUVMGYIPOWLAH-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- VCZANYLMPFRUHG-UHFFFAOYSA-N 2-naphthalen-2-ylethanol Chemical compound C1=CC=CC2=CC(CCO)=CC=C21 VCZANYLMPFRUHG-UHFFFAOYSA-N 0.000 description 1
- BQPBZDSDFCDSAO-UHFFFAOYSA-N 2-naphthalen-2-yloxyethanol Chemical compound C1=CC=CC2=CC(OCCO)=CC=C21 BQPBZDSDFCDSAO-UHFFFAOYSA-N 0.000 description 1
- HPEHFFOUTHKAOM-UHFFFAOYSA-N 2-phenoxy-4-piperazin-1-ylpyrimidine Chemical compound C1CNCCN1C1=CC=NC(OC=2C=CC=CC=2)=N1 HPEHFFOUTHKAOM-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZMRFRBHYXOQLDK-UHFFFAOYSA-N 2-phenylethanethiol Chemical compound SCCC1=CC=CC=C1 ZMRFRBHYXOQLDK-UHFFFAOYSA-N 0.000 description 1
- BDCFWIDZNLCTMF-UHFFFAOYSA-N 2-phenylpropan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1 BDCFWIDZNLCTMF-UHFFFAOYSA-N 0.000 description 1
- AVLPUUOYNXJFSZ-UHFFFAOYSA-N 2-piperazin-1-yl-6-(1,2,3,4-tetrahydronaphthalen-1-yloxy)pyrazine Chemical compound C12=CC=CC=C2CCCC1OC(N=1)=CN=CC=1N1CCNCC1 AVLPUUOYNXJFSZ-UHFFFAOYSA-N 0.000 description 1
- UWDAKILYEHECEL-UHFFFAOYSA-N 2-piperazin-1-yl-6-(2-pyridin-3-ylethoxy)pyrazine Chemical compound C=1N=CC(N2CCNCC2)=NC=1OCCC1=CC=CN=C1 UWDAKILYEHECEL-UHFFFAOYSA-N 0.000 description 1
- UNGPANLOBHWTGB-UHFFFAOYSA-N 2-piperazin-1-yl-6-(3-pyridin-2-ylpropoxy)pyrazine Chemical compound C=1C=CC=NC=1CCCOC(N=1)=CN=CC=1N1CCNCC1 UNGPANLOBHWTGB-UHFFFAOYSA-N 0.000 description 1
- QUOYSAHPSMJRSS-UHFFFAOYSA-N 2-piperazin-1-yl-6-(thiophen-3-ylmethoxy)pyrazine Chemical compound C1=CSC=C1COC(N=1)=CN=CC=1N1CCNCC1 QUOYSAHPSMJRSS-UHFFFAOYSA-N 0.000 description 1
- LMZJWZCRNARKIC-UHFFFAOYSA-N 2-piperazin-1-yl-6-[(3-pyrrol-1-ylthiophen-2-yl)methoxy]pyrazine Chemical compound S1C=CC(N2C=CC=C2)=C1COC(N=1)=CN=CC=1N1CCNCC1 LMZJWZCRNARKIC-UHFFFAOYSA-N 0.000 description 1
- ONURQVBEBKHJCL-UHFFFAOYSA-N 2-piperazin-1-yl-6-[(4-pyridin-2-ylphenyl)methoxy]pyrazine Chemical compound C=1C=C(C=2N=CC=CC=2)C=CC=1COC(N=1)=CN=CC=1N1CCNCC1 ONURQVBEBKHJCL-UHFFFAOYSA-N 0.000 description 1
- BOPDZAHTVWCPBT-UHFFFAOYSA-N 2-piperazin-1-yl-6-[[4-(trifluoromethyl)phenyl]methoxy]pyrazine Chemical compound C1=CC(C(F)(F)F)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 BOPDZAHTVWCPBT-UHFFFAOYSA-N 0.000 description 1
- ZRWDRUUBWGBNPO-UHFFFAOYSA-N 2-piperazin-1-yl-6-prop-2-ynoxypyrazine Chemical compound C#CCOC1=CN=CC(N2CCNCC2)=N1 ZRWDRUUBWGBNPO-UHFFFAOYSA-N 0.000 description 1
- RELPOLSGTUYMFR-UHFFFAOYSA-N 2-piperazin-1-ylquinoxaline Chemical class C1CNCCN1C1=CN=C(C=CC=C2)C2=N1 RELPOLSGTUYMFR-UHFFFAOYSA-N 0.000 description 1
- YPWSASPSYAWQRK-UHFFFAOYSA-N 2-pyridin-3-ylethanol Chemical compound OCCC1=CC=CN=C1 YPWSASPSYAWQRK-UHFFFAOYSA-N 0.000 description 1
- QIPHYKKDPODKOZ-UHFFFAOYSA-N 2-quinolin-8-yloxyethanol Chemical compound C1=CN=C2C(OCCO)=CC=CC2=C1 QIPHYKKDPODKOZ-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MGSHXMOLUWTMGP-UHFFFAOYSA-N 3'-carboxy-alpha-chromanol Chemical compound C1=CC=C2C(O)CCOC2=C1 MGSHXMOLUWTMGP-UHFFFAOYSA-N 0.000 description 1
- OIXRZHFZHRSXMN-UHFFFAOYSA-N 3-(2h-indazol-3-yl)propan-1-amine Chemical class C1=CC=C2C(CCCN)=NNC2=C1 OIXRZHFZHRSXMN-UHFFFAOYSA-N 0.000 description 1
- PCOFIIVWHXIDGT-UHFFFAOYSA-N 3-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=CC(C#N)=C1 PCOFIIVWHXIDGT-UHFFFAOYSA-N 0.000 description 1
- BOWIFWCBNWWZOG-UHFFFAOYSA-N 3-Thiophenemethanol Chemical compound OCC=1C=CSC=1 BOWIFWCBNWWZOG-UHFFFAOYSA-N 0.000 description 1
- SBTRALXZJBNYHG-UHFFFAOYSA-N 3-[(6-chloropyrazin-2-yl)oxymethyl]-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(COC=2N=C(Cl)C=NC=2)=C1 SBTRALXZJBNYHG-UHFFFAOYSA-N 0.000 description 1
- VUWKVBAVTZJJEI-UHFFFAOYSA-N 3-methoxy-2-(phenoxymethyl)benzaldehyde Chemical compound COC1=CC=CC(C=O)=C1COC1=CC=CC=C1 VUWKVBAVTZJJEI-UHFFFAOYSA-N 0.000 description 1
- JMIIDKDBGDGVJC-UHFFFAOYSA-N 3-naphthalen-2-yloxypropan-1-ol Chemical compound C1=CC=CC2=CC(OCCCO)=CC=C21 JMIIDKDBGDGVJC-UHFFFAOYSA-N 0.000 description 1
- FVZXYJDGVYLMDB-UHFFFAOYSA-N 3-pyridin-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CC=N1 FVZXYJDGVYLMDB-UHFFFAOYSA-N 0.000 description 1
- SAYKNBQCVYQQJF-UHFFFAOYSA-N 4-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(C#CC=2C=CC=CC=2)=C1 SAYKNBQCVYQQJF-UHFFFAOYSA-N 0.000 description 1
- MOOUWXDQAUXZRG-UHFFFAOYSA-N 4-(trifluoromethyl)benzyl alcohol Chemical compound OCC1=CC=C(C(F)(F)F)C=C1 MOOUWXDQAUXZRG-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- ZSDWZRCUSAPCGE-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]-2-piperazin-1-ylpyrimidine Chemical compound C1=CC(F)=CC=C1COC1=CC=NC(N2CCNCC2)=N1 ZSDWZRCUSAPCGE-UHFFFAOYSA-N 0.000 description 1
- JBSOLWKCGYDEAL-UHFFFAOYSA-N 4-[(6-chloropyrazin-2-yl)oxymethyl]-1h-indole Chemical compound ClC1=CN=CC(OCC=2C=3C=CNC=3C=CC=2)=N1 JBSOLWKCGYDEAL-UHFFFAOYSA-N 0.000 description 1
- ZVWHQZCMGCXQMP-UHFFFAOYSA-N 4-[2-(6-chloropyrazin-2-yl)oxyethyl]-5-methyl-2-phenyl-1,3-oxazole Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC1=CN=CC(Cl)=N1 ZVWHQZCMGCXQMP-UHFFFAOYSA-N 0.000 description 1
- WYQGVVAVUBXSNA-UHFFFAOYSA-N 4-[2-(6-chloropyrazin-2-yl)oxyethyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1CCOC1=CN=CC(Cl)=N1 WYQGVVAVUBXSNA-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- MWUVGXCUHWKQJE-UHFFFAOYSA-N 4-fluorophenethyl alcohol Chemical compound OCCC1=CC=C(F)C=C1 MWUVGXCUHWKQJE-UHFFFAOYSA-N 0.000 description 1
- GWFXUKHESASWJZ-UHFFFAOYSA-N 4-methyl-5-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethyl]-1,3-thiazole Chemical compound N1=CSC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1C GWFXUKHESASWJZ-UHFFFAOYSA-N 0.000 description 1
- QWLHJVDRPZNVBS-UHFFFAOYSA-N 4-phenoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OC1=CC=CC=C1 QWLHJVDRPZNVBS-UHFFFAOYSA-N 0.000 description 1
- OYQUCYCSSADEIC-UHFFFAOYSA-N 4-phenoxybutan-1-ol Chemical compound OCCCCOC1=CC=CC=C1 OYQUCYCSSADEIC-UHFFFAOYSA-N 0.000 description 1
- BRNVPFAGHJDDTG-UHFFFAOYSA-N 4-piperazin-1-yl-2-[[3-(trifluoromethoxy)phenyl]methoxy]pyrimidine Chemical compound FC(F)(F)OC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 BRNVPFAGHJDDTG-UHFFFAOYSA-N 0.000 description 1
- NMLYGLCBSFKJFI-UHFFFAOYSA-N 4-pyridin-2-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=N1 NMLYGLCBSFKJFI-UHFFFAOYSA-N 0.000 description 1
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- DPZMVZIQRMVBBW-UHFFFAOYSA-N 5-Phenyl-1-pentanol Chemical compound OCCCCCC1=CC=CC=C1 DPZMVZIQRMVBBW-UHFFFAOYSA-N 0.000 description 1
- CRNDXEVHWDPJSJ-UHFFFAOYSA-N 5-amino-1-ethyl-6,8-difluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=C(N)C(F)=C1N1CCNCC1 CRNDXEVHWDPJSJ-UHFFFAOYSA-N 0.000 description 1
- CRLDWFVRQNUUSZ-UHFFFAOYSA-N 5-fluoro-2-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C=C1C=O CRLDWFVRQNUUSZ-UHFFFAOYSA-N 0.000 description 1
- CDRCNCMLLKIQNT-UHFFFAOYSA-N 5-phenoxypentan-1-ol Chemical compound OCCCCCOC1=CC=CC=C1 CDRCNCMLLKIQNT-UHFFFAOYSA-N 0.000 description 1
- WWPKRXOOVICNJY-UHFFFAOYSA-N 6-methoxynaphthalen-2-ol Chemical compound C1=C(O)C=CC2=CC(OC)=CC=C21 WWPKRXOOVICNJY-UHFFFAOYSA-N 0.000 description 1
- IBVRNLCFTHSDEM-UHFFFAOYSA-N 6h-quinoxalin-5-one Chemical compound C1=CN=C2C(=O)CC=CC2=N1 IBVRNLCFTHSDEM-UHFFFAOYSA-N 0.000 description 1
- WUDRIEMLEHRNSY-UHFFFAOYSA-N 7-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethoxy]isoquinoline Chemical compound C=1C=C2C=CN=CC2=CC=1OCCOC(N=1)=CN=CC=1N1CCNCC1 WUDRIEMLEHRNSY-UHFFFAOYSA-N 0.000 description 1
- AYKKNCZWZNXBGY-UHFFFAOYSA-N 7-methoxy-2h-chromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)COC2=CC(OC)=CC=C21 AYKKNCZWZNXBGY-UHFFFAOYSA-N 0.000 description 1
- UNFNRIIETORURP-UHFFFAOYSA-N 7-methoxynaphthalen-2-ol Chemical compound C1=CC(O)=CC2=CC(OC)=CC=C21 UNFNRIIETORURP-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GDJXPGHINYOZSB-UHFFFAOYSA-N 8-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethoxy]quinolin-2-amine Chemical compound C12=NC(N)=CC=C2C=CC=C1OCCOC(N=1)=CN=CC=1N1CCNCC1 GDJXPGHINYOZSB-UHFFFAOYSA-N 0.000 description 1
- IWCBSSCFENRTKO-UHFFFAOYSA-N 8-[2-(6-piperazin-1-ylpyrazin-2-yl)oxyethoxy]quinoline Chemical compound C=1C=CC2=CC=CN=C2C=1OCCOC(N=1)=CN=CC=1N1CCNCC1 IWCBSSCFENRTKO-UHFFFAOYSA-N 0.000 description 1
- QKEBGAUJUHZNNU-UHFFFAOYSA-N 9h-pyrrolo[2,3-f]quinoxaline Chemical class N1=CC=NC2=C(NC=C3)C3=CC=C21 QKEBGAUJUHZNNU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- GCISKFHXQKMRRH-FEGZNKODSA-N C(\C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)OC1=CN=CC(=N1)N1[C@@H](CNCC1)C Chemical compound C(\C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)OC1=CN=CC(=N1)N1[C@@H](CNCC1)C GCISKFHXQKMRRH-FEGZNKODSA-N 0.000 description 1
- SLHCMPVPVQSTBV-UHFFFAOYSA-N C1=CNC2=C3C=CN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=CN=C3C=CC2=C1 SLHCMPVPVQSTBV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BHUIUXNAPJIDOG-UHFFFAOYSA-N Piperonol Chemical compound OCC1=CC=C2OCOC2=C1 BHUIUXNAPJIDOG-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWQOQQVKVOOHTI-SSDOTTSWSA-N [(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methanol Chemical compound C1=CC=C2O[C@H](CO)COC2=C1 GWQOQQVKVOOHTI-SSDOTTSWSA-N 0.000 description 1
- CPZRYQJPVUJHOS-UHFFFAOYSA-N [2-(2-phenylethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CCC1=CC=CC=C1 CPZRYQJPVUJHOS-UHFFFAOYSA-N 0.000 description 1
- TWQNSHZTQSLJEE-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1C(F)(F)F TWQNSHZTQSLJEE-UHFFFAOYSA-N 0.000 description 1
- YTUXZVSDDHCTBZ-UHFFFAOYSA-N [3-(dimethylamino)phenyl]methanol Chemical compound CN(C)C1=CC=CC(CO)=C1 YTUXZVSDDHCTBZ-UHFFFAOYSA-N 0.000 description 1
- XRGSSROOYSFMMS-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]methanol Chemical compound OCC1=CC=CC(OC(F)(F)F)=C1 XRGSSROOYSFMMS-UHFFFAOYSA-N 0.000 description 1
- LCOKNYKYZBDDDH-UHFFFAOYSA-N [3-methoxy-2-(phenoxymethyl)phenyl]methanol Chemical compound COC1=CC=CC(CO)=C1COC1=CC=CC=C1 LCOKNYKYZBDDDH-UHFFFAOYSA-N 0.000 description 1
- OFTUOABIHLBUAS-UHFFFAOYSA-N [4-(2-phenylethynyl)thiophen-2-yl]methanol Chemical compound S1C(CO)=CC(C#CC=2C=CC=CC=2)=C1 OFTUOABIHLBUAS-UHFFFAOYSA-N 0.000 description 1
- ZLCIFBOMXUAJPZ-UHFFFAOYSA-N [4-[3-(dimethylamino)propoxy]phenyl]methanol Chemical compound CN(C)CCCOC1=CC=C(CO)C=C1 ZLCIFBOMXUAJPZ-UHFFFAOYSA-N 0.000 description 1
- GQHKNJRCVPQMQL-UHFFFAOYSA-N [5-(4-chlorophenyl)-2-methylfuran-3-yl]methanol Chemical compound OCC1=C(C)OC(C=2C=CC(Cl)=CC=2)=C1 GQHKNJRCVPQMQL-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MFGWMAAZYZSWMY-UHFFFAOYSA-N beta-naphthyl carbinol Natural products C1=CC=CC2=CC(CO)=CC=C21 MFGWMAAZYZSWMY-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- WCRKBMABEPCYII-UHFFFAOYSA-N isoquinolin-7-ol Chemical compound C1=CN=CC2=CC(O)=CC=C21 WCRKBMABEPCYII-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- CUOBTXYMWOBWPK-UHFFFAOYSA-N n,n-dimethyl-3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]aniline Chemical compound CN(C)C1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 CUOBTXYMWOBWPK-UHFFFAOYSA-N 0.000 description 1
- BTFDGABXJCFHBZ-UHFFFAOYSA-N n,n-dimethyl-3-[4-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]phenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(C)C)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 BTFDGABXJCFHBZ-UHFFFAOYSA-N 0.000 description 1
- SGUBXKWIXLLZPM-UHFFFAOYSA-N n-benzyl-4-piperazin-1-ylpyrimidin-2-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=NC=CC=1N1CCNCC1 SGUBXKWIXLLZPM-UHFFFAOYSA-N 0.000 description 1
- MZFUMPVDVRKDPB-UHFFFAOYSA-N n-benzyl-6-piperazin-1-ylpyrazin-2-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=CN=CC=1N1CCNCC1 MZFUMPVDVRKDPB-UHFFFAOYSA-N 0.000 description 1
- AELLFKPPLQHPRV-UHFFFAOYSA-N n-propan-2-yl-7-propan-2-yliminocyclohepta-1,3,5-trien-1-amine Chemical compound CC(C)NC1=CC=CC=CC1=NC(C)C AELLFKPPLQHPRV-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- MQDVUDAZJMZQMF-UHFFFAOYSA-N pyridin-2-ylurea Chemical class NC(=O)NC1=CC=CC=N1 MQDVUDAZJMZQMF-UHFFFAOYSA-N 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical class C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 description 1
- 150000005592 pyrroloindoles Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000198 serotonin 5-HT3 receptor agonist Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0004245A SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Novel compounds and their use |
US25350900P | 2000-11-28 | 2000-11-28 | |
PCT/SE2001/002569 WO2002040456A1 (en) | 2000-11-20 | 2001-11-20 | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20032252D0 NO20032252D0 (no) | 2003-05-19 |
NO20032252L NO20032252L (no) | 2003-07-18 |
NO325181B1 true NO325181B1 (no) | 2008-02-11 |
Family
ID=26655311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032252A NO325181B1 (no) | 2000-11-20 | 2003-05-19 | Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1335907B1 (es) |
JP (2) | JP4387103B2 (es) |
KR (1) | KR100846339B1 (es) |
CN (1) | CN1267424C (es) |
AT (1) | ATE470662T1 (es) |
AU (2) | AU2002224266B2 (es) |
BR (1) | BR0115400A (es) |
CA (1) | CA2448729A1 (es) |
DE (1) | DE60142355D1 (es) |
HK (2) | HK1061855A1 (es) |
IL (2) | IL155702A0 (es) |
MX (1) | MXPA03004390A (es) |
NO (1) | NO325181B1 (es) |
NZ (1) | NZ525700A (es) |
PL (1) | PL361690A1 (es) |
WO (1) | WO2002040456A1 (es) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076925A2 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
WO2003072548A1 (en) * | 2002-02-22 | 2003-09-04 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
SE0201544D0 (sv) * | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
EP1513831B1 (en) | 2002-06-19 | 2010-01-06 | Biovitrum AB (publ) | Novel compounds, their use and preparation |
US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
ATE374766T1 (de) | 2003-01-14 | 2007-10-15 | Arena Pharm Inc | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CA2514220C (en) * | 2003-01-29 | 2012-02-28 | Pharmagene Laboratories Limited | Ep4 receptor antagonists |
CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
CN1902177A (zh) | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
MXPA06003615A (es) | 2003-09-30 | 2006-06-05 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
JP4529116B2 (ja) * | 2003-10-16 | 2010-08-25 | 東レ・ファインケミカル株式会社 | 高純度トリチルピペラジン誘導体の製造方法 |
WO2005053688A1 (en) | 2003-11-26 | 2005-06-16 | Alcon, Inc. | Substituted furo[2,3-g] indazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
EP1694670A1 (en) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
BRPI0518241A (pt) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
AU2006228378A1 (en) | 2005-03-31 | 2006-10-05 | Pfizer Products Inc. | Cyclopentapyridine and tetrahydroquinoline derivatives |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
TWI440456B (zh) | 2007-01-16 | 2014-06-11 | 用於治療代謝性症候群之新穎化合物 | |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PE20110852A1 (es) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012030953A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EA201391254A1 (ru) | 2011-03-01 | 2014-02-28 | Синерджи Фармасьютикалз Инк. | Способ получения агонистов гуанилатциклазы c |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CN104135859B (zh) * | 2011-12-28 | 2017-06-27 | 全球血液疗法公司 | 取代的苯甲醛化合物及其用于增加组织氧合的方法 |
RU2014150494A (ru) * | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Пирролидиногетероциклы |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
JP6463327B2 (ja) | 2013-03-15 | 2019-01-30 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
DK3102208T4 (da) | 2014-02-07 | 2024-08-26 | Global Blood Therapeutics Inc | Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
EP3383392A1 (en) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP3982949A4 (en) * | 2019-06-14 | 2023-10-11 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202227417A (zh) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | 雙環庚烷吡咯啶之食慾素受體促效劑 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954502A (en) * | 1988-06-10 | 1990-09-04 | Bristol-Myers Squibb Company | 1-indolyalkyl-4-(substituted-pyridinyl)piperazines |
IE911774A1 (en) * | 1990-06-11 | 1991-12-18 | Akzo Nv | Pyridinylpiperazine derivatives |
WO1994011363A1 (en) * | 1992-11-09 | 1994-05-26 | Asahi Kasei Kogyo Kabushiki Kaisha | 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivative, process for producing the same, and use thereof |
JPH07300474A (ja) * | 1994-05-02 | 1995-11-14 | Asahi Chem Ind Co Ltd | テトラハイドロキノキサリン誘導体およびその用途 |
FR2761071B1 (fr) * | 1997-03-20 | 1999-12-03 | Synthelabo | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique |
GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
CA2345146C (en) * | 1998-09-22 | 2010-02-23 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivative |
FR2788772B1 (fr) * | 1999-01-26 | 2001-03-02 | Adir | Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU772446B2 (en) * | 1999-02-24 | 2004-04-29 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists |
-
2001
- 2001-11-20 PL PL01361690A patent/PL361690A1/xx not_active Application Discontinuation
- 2001-11-20 IL IL15570201A patent/IL155702A0/xx unknown
- 2001-11-20 BR BR0115400-1A patent/BR0115400A/pt not_active IP Right Cessation
- 2001-11-20 DE DE60142355T patent/DE60142355D1/de not_active Expired - Lifetime
- 2001-11-20 CA CA002448729A patent/CA2448729A1/en not_active Abandoned
- 2001-11-20 AT AT01996532T patent/ATE470662T1/de not_active IP Right Cessation
- 2001-11-20 AU AU2002224266A patent/AU2002224266B2/en not_active Ceased
- 2001-11-20 WO PCT/SE2001/002569 patent/WO2002040456A1/en active IP Right Grant
- 2001-11-20 KR KR1020037006824A patent/KR100846339B1/ko not_active IP Right Cessation
- 2001-11-20 NZ NZ525700A patent/NZ525700A/xx unknown
- 2001-11-20 JP JP2002542784A patent/JP4387103B2/ja not_active Expired - Fee Related
- 2001-11-20 EP EP01996532A patent/EP1335907B1/en not_active Expired - Lifetime
- 2001-11-20 CN CNB018204058A patent/CN1267424C/zh not_active Expired - Fee Related
- 2001-11-20 AU AU2426602A patent/AU2426602A/xx active Pending
- 2001-11-20 MX MXPA03004390A patent/MXPA03004390A/es active IP Right Grant
-
2003
- 2003-05-01 IL IL155702A patent/IL155702A/en not_active IP Right Cessation
- 2003-05-19 NO NO20032252A patent/NO325181B1/no not_active IP Right Cessation
-
2004
- 2004-07-06 HK HK04104869A patent/HK1061855A1/xx not_active IP Right Cessation
-
2007
- 2007-06-13 HK HK07106358.6A patent/HK1099292A1/xx not_active IP Right Cessation
-
2009
- 2009-06-23 JP JP2009148822A patent/JP2009280587A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20030060947A (ko) | 2003-07-16 |
WO2002040456A1 (en) | 2002-05-23 |
NO20032252D0 (no) | 2003-05-19 |
HK1099292A1 (en) | 2007-08-10 |
CA2448729A1 (en) | 2002-05-23 |
NO20032252L (no) | 2003-07-18 |
ATE470662T1 (de) | 2010-06-15 |
JP4387103B2 (ja) | 2009-12-16 |
JP2009280587A (ja) | 2009-12-03 |
JP2004532806A (ja) | 2004-10-28 |
BR0115400A (pt) | 2003-09-30 |
CN1267424C (zh) | 2006-08-02 |
EP1335907B1 (en) | 2010-06-09 |
IL155702A (en) | 2010-05-31 |
AU2002224266B2 (en) | 2007-05-24 |
CN1479727A (zh) | 2004-03-03 |
HK1061855A1 (en) | 2004-10-08 |
DE60142355D1 (de) | 2010-07-22 |
NZ525700A (en) | 2004-12-24 |
PL361690A1 (en) | 2004-10-04 |
IL155702A0 (en) | 2003-11-23 |
AU2426602A (en) | 2002-05-27 |
EP1335907A1 (en) | 2003-08-20 |
MXPA03004390A (es) | 2004-05-14 |
KR100846339B1 (ko) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO325181B1 (no) | Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor | |
US6593330B2 (en) | Compounds and their use | |
AU2002224266A1 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor | |
AU777276B2 (en) | Novel compounds, their use and preparation | |
US6465467B1 (en) | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | |
AU2003228196B2 (en) | Novel compounds and their use | |
CA2449899C (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor | |
CN101035533B (zh) | 抗精神分裂症的双重nk1/nk3拮抗剂 | |
KR20020082229A (ko) | 아데노신 수용체 조절인자 | |
AU2011249167A1 (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
US20050171131A1 (en) | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | |
TW200404067A (en) | New compounds | |
KR20140138654A (ko) | 트리아지논 화합물 및 t형 칼슘채널 저해제 | |
NZ503604A (en) | 2-substituted 1,2-benzoisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) | |
NZ536688A (en) | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5HT-2 receptors | |
JP2003502317A (ja) | 新規化合物、その使用および製造 | |
TWI291958B (en) | Pyrazinyl-piperazine compounds, their use in the treatment of serotonin related diseases, and their preparation | |
AU2004202227A1 (en) | Novel compounds, their use and preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |